The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljac109 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Ali Al-Janabi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manche…. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Psoriasis Association, Department of Health, National Institute for Health Research.
Abstract (Originalsprache)
Background
Biologic and nonbiologic immunomodulators, used to treat immune-mediated inflammatory diseases (IMIDs), could impair the immune response to COVID-19 vaccines and thus vaccine effectiveness.
Objectives
Our objective was to investigate the association between biologic and nonbiologic immunomodulators and seroconversion following the first and second dose of COVID-19 vaccines in patients with IMIDs.
Methods
Serum samples were collected following the first or second dose of the BNT162b2 or AZD1222 vaccines from patients receiving biologic and/or nonbiologic immunomodulators for one or more of psoriasis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease or systemic lupus erythematosus. Seroconversion was defined as a positive Roche Elecsys® Anti-SARS-CoV-2 S (spike protein subunit S1/receptor binding domain) immunoassay (≥ 0.8 U mL–1). Association between immunomodulator exposure and seroconversion was assessed using logistic regression, adjusting for age and sex.
Results
After excluding those with prior COVID-19, post-first vaccine dose samples from 193 participants and post-second dose samples from 312 participants were included in the analysis. Following the first vaccine dose, 17.6% (n = 34) of participants did not seroconvert. Seroconversion was reduced for those on nonbiologic [adjusted odds ratio (OR) 0.29, 95% confidence interval (CI) 0.12–0.69] or combined nonbiologic and biologic treatment (adjusted OR 0.14, 95% CI 0.045–0.45) compared with those on biologic monotherapy. Subgroup analysis demonstrated reduced odds of seroconversion in those on methotrexate (adjusted OR 0.097, 95% CI 0.19–0.49) or prednisolone treatment (adjusted OR 0.044, 95% CI 0.002–1.00) relative to tumour necrosis factor-α inhibitor monotherapy. No participants receiving rituximab (n < 5) seroconverted after the first vaccine dose. Following the second vaccine dose, 1.6% of all participants did not seroconvert. Non-seroconversion was associated with receiving rituximab (n = 3 of 4) compared with those receiving other therapies (n = 2 of 308, P < 0.001). Post hoc analyses demonstrated that non-seroconversion was associated with age [adjusted OR 0.18, 95% CI 0.037–0.93 for those aged 60 years and over (reference category age 18–39 years)], but not sex, ethnicity or vaccine type.
Conclusions
Treatment with nonbiologics, particularly methotrexate, is associated with impaired seroconversion following two BNT162b2 or AZD1222 vaccine doses, in patients with IMIDs. These findings are consistent with those of other published studies. While this could indicate reduced protection against COVID-19, the immunological parameters that correlate most closely with vaccine effectiveness need to be defined to reach this conclusion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK.
- National Institute of Health Research, Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester NHS Foundation Trust, Manchester, UK.
- Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK.
- Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
- Affinity Biomarker Labs, Translation & Innovation Hub Building, Imperial College London White City Campus, London W12 0BZ, UK.
- Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.
ORCID-Profile: Ali Al-Janabi, Amelle Ra, Amy C Foulkes, Hector Chinoy, Kimme L Hyrich, Jimmy K Limdi, Zenas Z N Yiu, Christopher E M Griffiths, Richard B Warren
Förderung
- Psoriasis Association
- Department of Health
- National Institute for Health Research
- Manchester NIHR Biomedical Research Centre
- Medical Research Council
Zitieren
APA
Al-Janabi, A., Ra, A., Littlewood, Z., Foulkes, A. C., Hunter, H. J. A., Chinoy, H., Moriarty, C. A., Hyrich, K. L., Limdi, J. K., Yiu, Z. Z. N., Griffiths, C. E. M., & Warren, R. B. (2023). The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljac109
Vancouver
Al-Janabi A, Ra A, Littlewood Z, Foulkes AC, Hunter HJA, Chinoy H, et al. The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljac109
BibTeX
@article{AlJanabi2023,
author = {Al-Janabi, Ali and Ra, Amelle and Littlewood, Zoe and Foulkes, Amy C and Hunter, Hamish J A and Chinoy, Hector and Moriarty, Christopher A and Hyrich, Kimme L and Limdi, Jimmy K and Yiu, Zenas Z N and Griffiths, Christopher E M and Warren, Richard B},
title = {The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljac109}
}
EUVIMED